Russell D. Cohen, MD
Dr. Cohen is Associate Professor of Medicine in the Department of Medicine/Section of Gastroenterology at the University of Chicago in Illinois. In addition, he is Co-Director of Clinical...
Read More
Marc D. Cohen, MD
Dr. Cohen is Professor of Medicine with the National Jewish Medical and Research Center in Denver, Colorado. Dr. Cohen graduated from the George University School of Medicine and Health Science...
Read More
Since most experts predict there will be bioterrorism attacks and they may in fact come sooner rather than later, the United States Health Care System must be prepared to care for patients who are both injured but to also care for citizens in the locality who have been exposed to various agents of bioterrorism. This program is designed to help individual clinicians to be better prepared to fully participate in these efforts. All healthcare systems, including both the public and private...
Read More
This activity presented by...
Craig Martin, PharmD, BCPS
Clinical Pharmacy Specialist, Infectious Diseases
University of Kentucky Medical Center,...
Human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) remain one of the leading causes of death in the United States (US). As of December 2004, an estimated 944,306 persons have received a diagnosis of AIDS and of these, 529,113 have died. Since 1994, the annual number of HIV cases among blacks and other racial/ethnic minority populations, as well as new groups of individuals exposed through heterosexual contact has increased...
Read More
This activity presented by...
Patricia R. Jennings, DrPH, PA-C
Professor, University of Alabama at Birmingham
Project Director, Alabama/North Carolina
...
Biologic agents that block TNF have proven highly effective in improving the signs and symptoms of rheumatoid arthritis (RA), preventing the progression of joint damage, and improving functional status and quality of life. The introduction of TNF inhibitors has helped elevate the goals of treating RA, such that low disease activity or even remission are commonly considered appropriate therapeutic aims. Although they can be effective, up to half of patients treated with TNF inhibitors may...
Read More
This activity presented by...
Paul M. Ridker, MD, MPH, FACC, FAHA
Eugene Braunwald Professor of Medicine, Harvard Medical School
Director, Center for...
